Zeo ScientifiX, Inc. (ZEOX)

Market Cap	14.30M -16.9%
Revenue (ttm)	5.20M +12.5%
Net Income	-5.52M
EPS	-0.86
Shares Out	7.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	7,845
Open	1.850
Previous Close	1.850
Day's Range	1.830 - 1.890
52-Week Range	1.200 - 3.320
Beta	3.95
RSI	36.57
Earnings Date	Mar 17, 2026

About Zeo ScientifiX

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZEOX

Financial Performance

In fiscal year 2025, Zeo ScientifiX's revenue was $5.20 million, an increase of 12.53% compared to the previous year's $4.62 million. Losses were -$5.52 million, 17.3% more than in 2024.